Moderna Inc will apply for European and US emergency authorisation for its Covid-19 vaccine today after full results from a late-stage study showed it was 94.1 per cent effective with no serious safety concerns, the company said.
Moderna also reported that the vaccine's efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100 per cent success rate in preventing severe cases of a disease that has killed nearly 1.5 million people.
The filing sets Moderna's product up to be the second vaccine likely to receive emergency use authorisation this year following a shot developed by Pfizer and BioNTech which had a 95 per cent efficacy rate in trials.
"We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it," Moderna Chief Medical Officer Tal Zaks said.
"We expect to be playing a major part in turning around this pandemic."
Of the 196 volunteers who contracted Covid-19 in the trial with more than 30,000 people, 185 received a placebo while 11 got the vaccine.
Moderna reported 30 severe cases - all in the placebo group - which means the vaccine was 100 per cent effective in preventing severe cases.
Moderna said it would now seek conditional approval from the European Medicines Agency, which has already begun a rolling review of its data, and would continue to talk with other regulators.
Pfizer has already applied for emergency use authorisation in both Europe and the US, putting it about a week ahead of Moderna.
Moderna said it was on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people.
'Just overwhelming'
Both of the vaccines use a new technology called synthetic messenger RNA (mRNA) whereas others, such as Britain's AstraZeneca, are using more traditional methods to develop their vaccines.
AstraZeneca has announced an average efficacy rate of 70 per cent for its shot and as much as 90 per cent for a subgroup of trial participants who got a half dose, followed by a full dose.
But some scientists have expressed doubts about the robustness of the 90 per cent efficacy figure for the smaller group.
Moderna's latest efficacy result is slightly lower than an interim analysis released on November 16th of 94.5 per cent effectiveness, a difference that Zaks said was not statistically significant.
"At this level of effectiveness, when you just do the math of what it means for the pandemic that's raging around us, it's just overwhelming," said Zaks, who said he cried when he saw the final results over the weekend.
Both the Moderna and Pfizer vaccines proved more effective than anticipated and were far superior to the 50 per cent benchmark set by the US Food and Drug Administration (FDA).
Independent advisers to the FDA are scheduled to meet on December 17th to review Moderna's trial data and make a recommendation to the FDA. They will meet on Decemeber 10th to review Pfizer's data.
The distribution of the Moderna vaccine is expected to be easier than Pfizer's because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by the later.
